Real-world treatments and thrombotic events in polycythemia vera patients in the USA

Data from this retrospective observational study of medical and pharmacy claims of patients being treated for polycythemia vera (PV) suggest that currently available PV treatments may not be used to their full advantage. Among those patients initiating with phlebotomy monotherapy, the majority of high-risk (54%) and low-risk patients (64%) sometimes/always had hematocrit levels > 50%. Sixteen percent of all patients (20% of high-risk and 8% of low-risk) experienced at least one thrombotic event after starting treatment.